ABCL Stock Price, AbCellera Biologics Inc Quote, Chart

Market Summary

USD4.18-0.16

Market Closed

-3.69%

ABCL Stock Price

View Fullscreen

ABCL RSI Chart

ABCL Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-8.36

Price/Sales (Trailing)

32.18

EV/EBITDA

-7.29

Price/Free Cashflow

-10.13

ABCL Price/Sales (Trailing)

ABCL Profitability

EBT Margin

-457.67%

Return on Equity

-12.7%

Return on Assets

-9.84%

Free Cashflow Yield

-9.87%

ABCL Fundamentals

ABCL Revenue

Revenue (TTM)

38.0M

Rev. Growth (Yr)

-57.39%

Rev. Growth (Qtr)

39.1%

ABCL Earnings

Earnings (TTM)

-146.4M

Earnings Growth (Yr)

-57.73%

Earnings Growth (Qtr)

-64.8%

Breaking Down ABCL Revenue

Last 7 days

-6.9%

Last 30 days

-11.2%

Last 90 days

-16.4%

Trailing 12 Months

-43.4%

How does ABCL drawdown profile look like?

ABCL Financial Health

Current Ratio

7.33

ABCL Investor Care

Shares Dilution (1Y)

1.42%

Diluted EPS (TTM)

-0.52

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	373.6M	261.7M	149.9M	38.0M
2022	489.0M	507.3M	603.2M	485.4M
2021	431.2M	447.7M	443.8M	375.2M
2020	67.0M	122.4M	177.8M	233.2M
2019	0	0	0	11.6M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of AbCellera Biologics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 26, 2024	hansen carl l. g.	acquired	151,538	2.7	56,125	chief executive officer
Dec 19, 2023	thermopylae holdings ltd.	gifted	-	-	-210,000	-
Nov 23, 2023	hansen carl l. g.	acquired	151,538	2.7	56,125	chief executive officer
Nov 08, 2023	montalbano john s.	bought	44,600	4.46	10,000	-
Nov 06, 2023	montalbano john s.	bought	92,800	4.64	20,000	-
Sep 22, 2023	hayden michael r	bought	98,200	4.91	20,000	-
Sep 12, 2023	lecault veronique	bought	103,800	5.19	20,000	chief operating officer
Aug 24, 2023	hansen carl l. g.	acquired	151,538	2.7	56,125	chief executive officer
Aug 08, 2023	hayden michael r	bought	177,000	5.9	30,000	-
May 26, 2023	thermopylae holdings ltd.	bought	997,728	6.5211	153,000	-

Which funds bought or sold ABCL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	Financial Synergies Wealth Advisors, Inc.	sold off	-100	-902	-	-%
Apr 12, 2024	Pacifica Partners Inc.	added	78.82	17,801	39,443	0.02%
Apr 10, 2024	CVA Family Office, LLC	unchanged	-	-271	1,042	-%
Apr 10, 2024	Green Alpha Advisors, LLC	added	1.87	-30,480	128,412	0.09%
Apr 05, 2024	GAMMA Investing LLC	reduced	-14.81	-68.00	208	-%
Apr 05, 2024	NBC SECURITIES, INC.	added	6.48	-7,000	37,000	-%
Apr 02, 2024	AA Financial Advisors, LLC	new	-	57,100	57,100	0.04%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	222	1,142	-%
Mar 15, 2024	B. Riley Wealth Advisors, Inc.	added	85.71	63,045	111,345	-%
Mar 11, 2024	VANGUARD GROUP INC	new	-	74,870	74,870	-%

Are Funds Buying or Selling ABCL?

Are funds buying ABCL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ABCL

No. of Funds

Unveiling AbCellera Biologics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	baker bros. advisors lp	7.9%	22,909,753	SC 13G
Feb 13, 2024	hansen carl l. g.	20.6%	60,740,524	SC 13G/A
Jan 29, 2024	baillie gifford & co	8.29%	24,044,796	SC 13G/A
Apr 24, 2023	thiel peter	4.99%	14,360,427	SC 13D/A
Feb 13, 2023	capital world investors	3.3%	9,327,493	SC 13G/A
Feb 06, 2023	hansen carl l. g.	20.4%	58,993,307	SC 13G/A
Jan 18, 2023	baillie gifford & co	6.88%	19,696,735	SC 13G
Feb 14, 2022	dcvc bio, l.p.	2.6%	7,305,761	SC 13G/A
Feb 14, 2022	viking global investors lp	0.0%	0	SC 13G/A
Feb 11, 2022	capital world investors	7.8%	22,051,703	SC 13G

Recent SEC filings of AbCellera Biologics Inc

View All Filings

Date Filed	Form Type	Document
Feb 27, 2024	4	Insider Trading
Feb 23, 2024	8-K	Current Report
Feb 20, 2024	S-8	Employee Benefits Plan
Feb 20, 2024	8-K	Current Report
Feb 20, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Jan 29, 2024	SC 13G/A	Major Ownership Report
Jan 16, 2024	4	Insider Trading
Jan 16, 2024	4	Insider Trading

Peers (Alternatives to AbCellera Biologics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	0.01%	-33.89%	-8.42	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.06%	-27.57%	-42.25	10.17	76.23%	61.08%
BMRN	17.3B	2.4B	9.12%	-7.56%	103	7.14	15.42%	18.43%
INCY	12.0B	3.7B	-8.48%	-28.30%	20.07	3.25	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.27%	-36.41%	-11.74	15.65	425.83%	18.94%
BBIO	4.5B	-	-6.46%	74.90%	-6.94	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-9.62%	-0.34%	-13.52	11.95	440.80%	-27.84%
ARWR	3.0B	240.7M	-15.06%	-21.14%	-10.03	12.36	-1.03%	-92.09%
ACAD	2.8B	726.4M	-8.60%	-6.11%	-45.41	3.83	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.17%	-12.95%	25.42	4.56	85.90%	-14.05%
NVAX	576.6M	983.7M	-22.12%	-55.02%	-1.06	0.59	-50.36%	17.16%
CRBP	448.6M	881.7K	-2.13%	345.78%	-10.06	466.16	-77.61%	-5.33%
INO	256.8M	4.9M	2.33%	7.75%	-1.9	52.78	-54.97%	51.72%
IBIO	6.7M	2.1M	82.86%	81.13%	-0.25	2.14	-13.45%	66.37%

AbCellera Biologics Inc News

Latest updates

AbCellera Biologics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	39.1%	9.00	7.00	10.00	16.00	22.00	101	46.00	317	139	5.00	28.00	203	208	9.00	11.00	5.00	-
Operating Expenses	22.4%	75.00	61.00	61.00	77.00	59.00	64.00	54.00	92.00	58.00	34.00	35.00	45.00	47.00	11.00	12.00	7.00	-
S&GA Expenses	-10.6%	3.00	3.00	4.00	4.00	3.00	3.00	3.00	2.00	2.00	1.00	1.00	3.00	2.00	1.00	1.00	0.00	-
R&D Expenses	28.2%	49.00	38.00	36.00	53.00	28.00	27.00	27.00	26.00	17.00	17.00	15.00	12.00	9.00	7.00	9.00	4.00	-
EBITDA Margin	-367.5%	-3.94*	-0.84*	-0.23*	-0.08*	0.51*	0.60*	0.57*	0.60*	0.60*	0.68*	0.72*	-	-	-	-	-	-
Income Taxes	86.4%	-1.45	-10.67	-7.48	-8.04	-1.52	20.00	-0.10	62.00	25.00	-3.59	0.00	44.00	-	-	-	-	-
Earnings Before Taxes	-23.7%	-48.60	-39.28	-38.00	-48.15	-31.41	47.00	-6.89	231	85.00	-24.97	-2.07	161	156	-2.69	7.00	-2.09	-
EBT Margin	-337.3%	-4.58*	-1.05*	-0.27*	-0.11*	0.49*	0.59*	0.56*	0.59*	0.58*	0.65*	0.70*	-	-	-	-	-	-
Net Income	-64.8%	-47.15	-28.61	-30.53	-40.11	-29.89	27.00	-6.78	169	60.00	-21.38	-2.32	117	2.00	-2.69	7.00	-2.09	-
Net Income Margin	-346.8%	-3.85*	-0.86*	-0.28*	-0.13*	0.33*	0.41*	0.39*	0.42*	0.41*	0.21*	0.25*	-	-	-	-	-	-
Free Cashflow	-66.6%	-34.04	-20.44	-7.30	-59.05	19.00	-139	242	86.00	-26.14	-14.51	121	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-1.6%	1,488	1,512	1,537	1,498	1,541	1,552	1,594	1,592	1,319	1,173	1,152	1,129	1,006
Current Assets	-5.2%	872	920	931	941	1,025	1,046	1,144	1,174	930	804	864	908	813
Cash Equivalents	-22.7%	133	172	180	193	387	397	816	571	501	518	793	686	594
Net PPE	-100.0%	-	277	260	233	217	201	149	122	112	92.00	87.00	35.00	18.00
Goodwill	0.0%	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	49.00	32.00	32.00	32.00
Liabilities	1.9%	336	329	342	289	308	302	381	385	293	219	184	171	175
Current Liabilities	8.0%	119	110	119	90.00	118	106	221	213	121	50.00	70.00	88.00	103
Shareholder's Equity	-2.6%	1,152	1,183	1,195	1,209	1,233	1,250	1,213	1,208	1,026	953	968	957	831
Retained Earnings	-14.4%	280	327	356	386	426	456	429	436	268	208	229	231	114
Additional Paid-In Capital	10.7%	121	109	96.00	82.00	74.00	64.00	56.00	45.00	35.00	27.00	22.00	15.00	6.00
Shares Outstanding	1.4%	291	287	287	287	287	285	284	284	276	279	272	-	-
Float	-	-	-	1,464	-	-	-	2,404,552	-	-	-	3,794,989	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-18400.9%	-19,611	-106	19,903	-44,063	30,912	-126,786	273,015	100,219	-16,712	-5,932	157,683	109,545	1,278	-3,801	25,977	-764	-
Share Based Compensation	3.7%	16,448	15,862	16,399	15,474	13,323	11,754	12,113	12,291	9,038	7,708	8,473	5,427	4,622	1,932	606	1,237	-
Cashflow From Investing	-90.2%	-24,323	-12,786	-34,390	-149,609	-17,063	-281,994	-27,197	-26,371	-1,149	-269,626	-45,633	-15,839	-108,182	-3,885	-2,130	-5,583	-
Cashflow From Financing	-43.2%	3,765	6,630	419	-458	349	-19.00	1,173	-3,131	1,834	898	-5,075	-1,543	609,939	-14,370	346	87,738	-

ABCL Income Statement

2023-12-31

Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Revenues:

Total revenue

$ 38,025

$ 485,424

$ 375,203

Operating expenses:

Royalty fees

0

66,436

45,516

Research and development

^[1]

175,658

107,879

62,062

Sales and marketing

^[1]

14,180

11,270

6,913

General and administrative

^[1]

60,999

55,485

41,848

Depreciation, amortization, and impairment

24,395

27,843

14,451

Total operating expenses

275,232

268,913

170,790

Income (loss) from operations

(237,207)

216,511

204,413

Other (income) expense

Interest (income)

(42,247)

(16,079)

(3,330)

Grants and incentives

(14,155)

(10,554)

(17,486)

Other

(6,776)

4,045

6,080

Total other (income)

(63,178)

(22,588)

(14,736)

Net earnings (loss) before income tax

(174,029)

239,099

219,149

Income tax (recovery) expense

(27,631)

80,580

65,685

Net earnings (loss)

(146,398)

158,519

153,464

Foreign currency translation adjustment

(329)

(1,671)

280

Comprehensive income (loss)

$ (146,727)

$ 156,848

$ 153,744

Net earnings (loss) per share attributable to common shareholders

Basic (in dollars per share)

$ (0.51)

$ 0.56

Diluted (in dollars per share)

$ (0.51)

$ 0.50

$ 0.48

Weighted-average common shares outstanding

Basic (in shares)

289,166,486

285,056,606

275,763,745

Diluted (in shares)

289,166,486

314,827,255

318,294,236

Research fees

Revenues:

Total revenue

$ 35,556

$ 40,802

$ 19,076

Licensing revenue

Revenues:

Total revenue

969

696

20,778

Milestone payments

Revenues:

Total revenue

1,500

900

8,000

Royalty revenue

Revenues:

Total revenue

$ 0

$ 443,026

$ 327,349

[1]	Exclusive of depreciation, amortization, and impairment

ABCL Balance Sheet

2023-12-31

Consolidated Balance Sheets $ in Thousands, $ in Millions	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Current assets:
Cash and cash equivalents	$ 133,320	$ 386,535
Marketable securities	627,265	499,950
Total cash, cash equivalents, and marketable securities	760,585	886,485
Accounts and accrued receivable	30,590	38,593
Restricted cash	25,000	25,000
Other current assets	55,810	75,413
Total current assets	871,985	1,025,491
Long-term assets:
Property and equipment, net	287,696	217,255
Intangible assets, net	120,425	131,502
Goodwill	47,806	47,806
Investments in and loans to equity accounted investees	65,938	72,522
Other long-term assets	94,244	46,331
Total long-term assets	616,109	515,416
Total assets	1,488,094	1,540,907
Current liabilities:
Accounts payable and other liabilities	49,580	52,497
Contingent consideration payable	50,475	44,211
Deferred revenue	18,958	21,612
Total current liabilities	119,013	118,320
Long-term liabilities:
Operating lease liability	71,222	76,675
Deferred revenue	8,195	19,516
Deferred government contributions	95,915	40,801
Contingent consideration payable	4,913	16,054
Deferred tax liability	30,612	33,178
Other long-term liabilities	5,906	3,086
Total long-term liabilities	216,763	189,310
Total liabilities	335,776	307,630
Commitments and contingencies
Shareholders' equity:
Common shares: no par value, unlimited authorized shares at December 31, 2022 and December 31, 2023: 286,851,595 and 290,824,970 shares issued and outstanding at December 31, 2022 and December 31, 2023, respectively	753,199	734,365
Additional paid-in capital	121,052	74,118
Accumulated other comprehensive income (loss)	(1,720)	(1,391)
Accumulated earnings	279,787	426,185
Total shareholders' equity	1,152,318	1,233,277
Total liabilities and shareholders' equity	$ 1,488,094	$ 1,540,907

About AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

CEO	Dr. Carl L.G. Hansen Ph.D.
WEBSITE	abcellera.com
INDUSTRY	Biotechnology
EMPLOYEES	590

AbCellera Biologics Inc Frequently Asked Questions

What is the ticker symbol for AbCellera Biologics Inc? What does ABCL stand for in stocks?

ABCL is the stock ticker symbol of AbCellera Biologics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AbCellera Biologics Inc (ABCL)?

As of Mon Apr 15 2024, market cap of AbCellera Biologics Inc is 1.22 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABCL stock?

You can check ABCL's fair value in chart for subscribers.

What is the fair value of ABCL stock?

You can check ABCL's fair value in chart for subscribers. The fair value of AbCellera Biologics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AbCellera Biologics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABCL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AbCellera Biologics Inc a good stock to buy?

The fair value guage provides a quick view whether ABCL is over valued or under valued. Whether AbCellera Biologics Inc is cheap or expensive depends on the assumptions which impact AbCellera Biologics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABCL.

What is AbCellera Biologics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, ABCL's PE ratio (Price to Earnings) is -8.36 and Price to Sales (PS) ratio is 32.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABCL PE ratio will change depending on the future growth rate expectations of investors.